黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Indirubin-3’-monoxime acts as proteasome inhibitor:Therapeutic application in multiple myeloma

EBioMedicine. 2022-04; 
Zhen Yu , Xiaojing Wei , Lanting Liu , Hao Sun , Teng Fang , Lu Wang , Ying Li , Weiwei Sui , Kefei Wang , Yi He , Yaozhong Zhao , Wenyang Huang , Gang An , Fancui Meng , Changjiang Huang , Tengteng Yu , Kenneth C Anderson , Tao Cheng , Lugui Qiu , Mu Hao
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis Then, streptavidin MagBeads (#L00424, GenScript)36 were added to cell lysates and rocked gently at room temperature for extra 3 h, followed by PBS washing three times (1 mL for each time) to thoroughly remove the non-specifically bound proteins. Get A Quote

摘要

Background: Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment failure in clinical practice. Here, we investigated the effects of Indirubin-3'-monoxime (I3MO), one of the derivatives of Indirubin, in the treatment of MM. Methods: MM patient primary samples and human cell lines were examined. I3MO effects on myeloma treatment and the underling molecular mechanisms were investigated via in vivo and in vitro study. Findings: Our results demonstrated the anti-MM activity of I... More

关键词

Indirubin-3’-monoxime (I3MO); Multiple myeloma; PSME3 (PA28γ); PSME4 (PA200); Proteasome inhibition.